American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, to go Public through Business Combination with Digital Transformation Opportunities Corp.

/in /by
  • American Oncology Network (AON) is a rapidly growing network of community-based oncology practices
  • The proposed transaction values the combined company at a pro forma enterprise value of approximately $500 million

FORT MYERS, Fla. & LOS ANGELES, October 6, 2022 – American Oncology Network (“AON” or the “Company”), a rapidly growing network of community-based oncology practices, and Digital Transformation Opportunities Corp. (Nasdaq: DTOC) (“DTOC”), a special purpose acquisition company focused on the healthcare industry, today announced that they have entered into a definitive business combination agreement pursuant to which AON will become a public company (the “Business Combination”). Upon completion of the Business Combination, the combined company expects to be listed on Nasdaq.

Headquartered in Fort Myers, Florida, AON has grown significantly since it commenced operations in late 2018. The Company’s robust platform provides oncology practices with comprehensive support, access to revenue-diversifying adjacent services, and practice management expertise to empower physicians to make cancer care better. AON offers an innovative model of physician-led, community-based oncology management. With access to care-enhancing patient services (such as a centralized specialty pharmacy, diagnostics, pathology, as well as a fully integrated technology platform anchored by an oncology-specific electronic medical record system), a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences will be at the very pinnacle of cancer care today.

AON commenced operations in September 2018 and was founded by a senior leadership team who previously worked together and who have deep sector expertise within oncology. Since 2019, AON has generated compounded annual revenue growth of more than 60% through June 2022 and now generates more than $1 billion in annual revenue and operates profitably. AON’s platform currently includes 107 physicians and 24 practices across 71 locations in 18 states.

AON is well-positioned to continue growing driven by: (i) a fragmented and growing oncology industry with oncology medicine spend forecasted to grow at a 12% long-term CAGR, according to BCC Research; (ii) the ability to support the growth of AON’s physician partners through scaling ancillary services, such as clinical trials and dispensing of over 99% of oral oncolytics through AON’s specialty pharmacy, and introducing new service offerings; (iii) expanding AON’s existing service offering to address the broader oncology market; and (iv) growing the number of physician partners within AON’s network through both organic growth at existing practices as well as adding new practices.

Upon the closing of the Business Combination, AON’s senior leadership team will continue to serve in their current roles. The combined company will be led by AON’s Chief Executive Officer Todd Schonherz, President and Chief Development Officer Brad Prechtl, Chief Financial Officer David Gould, and Chief Medical Officer Dr. Fred Divers. AON’s existing board, which is composed of practicing medical oncologists, is expected to remain in place and will be joined by additional members affiliated with DTOC.

Management and Board of Directors’ Comments

Todd Schonherz, AON CEO, stated: “This transaction represents the next step in AON’s journey to become the leading platform for community-based oncology practices. Since launching the AON platform in 2018, we’ve been able to drive consistently strong growth by providing our physician partners with a strong suite of practice management tools and ancillary services as well as access to the financial benefits associated with being integrated with a scaled platform. We are excited to use the growth capital and partnership with the DTOC team to continue investing in technology and services that will support our physician partners and enhance the value proposition of AON.”

Kevin Nazemi, DTOC CEO, stated: “We are excited to partner with AON and believe that the Company is well-positioned to continue to build on its strong growth track record. We look forward to supporting AON as it continues to bring its services to more physician partnerships. We launched DTOC with the commitment to our investors to partner with a high growth platform that was leveraging technology to drive improvement within the healthcare industry and we couldn’t be more excited to fulfill that commitment today through our partnership with AON.”

Dr. Stephen “Fred” Divers, AON Chief Medical Officer, added: “AON was founded with the mission of providing community-based oncology practices with a platform that can support robust practice growth and deliver patient-centric care. We believe that the DTOC partnership will further enhance AON’s platform, allowing our physician partners to continue growing and thriving as part of our network. We look forward to continuing to grow our network of physician partners and supporting them with our physician practice management platform.”

Details of the Business Combination

Under the terms of the definitive business combination agreement, the proposed Business Combination values the combined company at a pro forma enterprise value of approximately $500 million. Existing AON equity holders will roll 100% of their equity in AON. DTOC’s sponsor has agreed to subject its shares in the combined company to lock-up restrictions and various earnout thresholds.

The proposed Business Combination, which has been approved by DTOC’s board of directors and AON’s board of managers and members, is expected to close in the first half of 2023. The closing of the proposed Business Combination is subject to approval by DTOC’s stockholders and other customary closing conditions, including any applicable regulatory approvals.

The description of the proposed Business Combination contained herein is only a summary and is qualified in its entirety by reference to the definitive agreement relating to the Business Combination, a copy of which will be filed by DTOC with the Securities and Exchange Commission (“SEC”) as an exhibit to a Current Report on Form 8-K, which can be accessed through the SEC’s website at www.sec.gov.

Advisors

Paul Hastings LLP is serving as legal advisor to DTOC. Woolery & Co. PLLC and Dentons US LLP are serving as legal advisors to AON.

About AON

The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 107 physicians practicing across 18 states. The executive management team of AON encompasses members with an average of more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

About DTOC

Digital Transformation Opportunities Corp. is a blank check company, led by Kevin Nazemi, former Co-Founder and Co-CEO of Oscar Health, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. DTOC’s Board of Directors includes Kevin Nazemi, Brad Fluegel (former Chief Strategy Officer of Walgreens and Anthem), Jim Moffatt (Former Vice Chairman and Global CEO of Deloitte Consulting), and Heather Zynczak (Former Chief Marketing Officer of Pluralsight and Domo). DTOC is focused on businesses operating in the healthcare industry. To learn more about Digital Transformation Opportunities Corp., visit www.dtocorp.com.

Important Information about the Transaction and Where to Find It

In connection with the proposed Business Combination, DTOC intends to file with the SEC a proxy statement, which will be mailed (if and when available) to all DTOC stockholders once definitive (the “Proxy Statement”), which will be distributed to holders of shares of DTOC common stock in connection with DTOC’s solicitation of proxies for the vote by DTOC stockholders with respect to the Business Combination as well as other matters as may be described in the Proxy Statement. DTOC STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ, WHEN AVAILABLE, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION, AS THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT DTOC, AON AND THE PROPOSED BUSINESS COMBINATION. This press release does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. When available, the Proxy Statement and other relevant materials for the proposed Business Combination will be mailed to stockholders of DTOC as of a record date to be established for voting on the proposed Business Combination. DTOC stockholders will also be able to obtain copies of the definitive proxy statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov.

Participants in the Solicitation

DTOC and its directors and executive officers may be deemed participants in the solicitation of proxies from DTOC’s stockholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in DTOC is contained in DTOC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on April 13, 2022 and is available free of charge at the SEC’s website at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Proxy Statement for the proposed Business Combination.

AON and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of DTOC in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the Proxy Statement for the proposed Business Combination.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. Forward-looking statements generally relate to future events including future financial or operating performance of DTOC or AON. For example, projections of future revenue and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by DTOC and its management, and AON and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond DTOC’s and AON’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) DTOC’s ability to complete the Business Combination and to raise additional capital; (2) the outcome of any legal proceedings that may be instituted against DTOC, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the stockholders of DTOC, to obtain financing to complete the Business Combination, or to satisfy other conditions to closing; (4) the amount of redemption requests made by DTOC’s public stockholders; (5) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (6) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (7) the risk that the Business Combination disrupts current plans and operations of AON as a result of the announcement and consummation of the Business Combination; (8) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (9) costs related to the Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that AON or the combined company may be adversely affected by other economic, business, and/or competitive factors; (12) AON’s estimates of expenses and profitability; (13) the failure to realize anticipated pro forma results or projections and underlying assumptions; and (14) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in DTOC’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 13, 2022 and DTOC’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 17, 2022, in the Proxy Statement relating to the Business Combination to be filed with the SEC, and in subsequent filings with the SEC. DTOC and AON caution that the foregoing list of factors is not exclusive or exhaustive and investors should not place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. If any of these risks materialize or DTOC’s or AON’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DTOC nor AON presently know or that DTOC and AON currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DTOC’s and AON’s expectations, plans or forecasts of future events and views as of the date of this communication. DTOC and AON anticipate that subsequent events and developments will cause DTOC’s and AON’s assessments to change. However, while DTOC may elect to update these forward-looking statements at some point in the future, DTOC and AON specifically disclaim any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing DTOC’s or AON’s assessments as of any date subsequent to the date of this communication. Neither DTOC nor AON gives any assurance that AON or DTOC will achieve its expectations. Accordingly, undue reliance should not be placed upon the forward-looking statements.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

References to Websites in this Press Release

The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Contacts

For AON:
David Gould, Chief Financial Officer
David.Gould@aoncology.com

For DTOC:
Kyle Francis, Chief Financial Officer
kyle@dtocorp.com

American Oncology Network Partners with RxLightning to Speed Access to Specialty Medications for Cancer Patients

/in /by

Community oncology practice sees 79 percent of patients enrolled in less than one day

FORT MYERS, Fla., October 5, 2022 – The American Oncology Network (AON) and RxLightning have partnered to provide AON’s community oncology practices with an all-digital approach to financial assistance enrollment for specialty medications. This partnership makes the complex burden of specialty medication enrollment simple for AON’s healthcare providers and allows patients quicker access to lifesaving medications.

RxLightning’s technology simplifies a historically cumbersome process by giving healthcare providers a way to easily submit specialty drug enrollment and patient assistance applications through a single digital source. Additionally, the platform safely and securely captures patient information to allow for future enrollments and applications to be submitted without delay.

AON introduced the digital platform to its in-network practices in May 2022. Since implementation, the practices are reaping the benefits of lightning-fast enrollments, including increased efficiency of application completions, reduced time for patient access to medications and increased patient satisfaction. Early results show RxLightning’s platform reduces the time patients have to wait for medication enrollment from over a week to 79% of patients enrolled in less than one day. When a patient needs specialty medication, this decrease in wait time is life-changing and a significant contrast to the antiquated paper form and fax method in which enrollment would take a week or longer.

“In a space where specialty medications often cost thousands of dollars, financial toxicity and the enrollment process for assistance can be very burdensome on the patient. Having the ability to avoid the lengthy process of manually filling out and mailing forms back and forth between the pharmacy, patient, clinic and manufacturer can significantly reduce the time to get access to medications, which is critical to the overall health success of cancer patients,” said Doug Braun, AON’s senior pharmacy director. “We are excited to have partnered with RxLightning. Our AON Pharmacy team is able to send financial assistance applications securely and electronically to patients, which ultimately facilitates getting medications out to patients sooner all while having a single platform that supports all medications we prescribe.”

“RxLightning is on a mission to create an ecosystem that benefits everyone, from patients to providers, health systems, payers and pharma manufacturers. Specialty medication access is cumbersome, prolonging life-changing treatment and leaving patients in the dark. Through our solution, we are seeing patients enrolled in a single day,” said Julia Regan, CEO and founder of RxLightning. “AON has been an exemplary partner, seeing the true benefits of RxLightning through improving new patient starts and a reduced turnaround time for therapy initiation. We look forward to our continued partnership and improving medication access for AON’s patients.”

“This partnership has given me the ability to quickly enroll my patients for the most beneficial specialty medication that is needed to treat their disease,” said Dr. Taral Patel, medical oncologist at Zangmeister Cancer Center. “The platform speeds up the enrollment process for medications, getting patients their medications quicker, which is critical for those with cancer.”

“Our values guide every decision we make,” said AON Chief Executive Officer Todd Schonherz. “Our C.A.R.E. values center on continuously supporting our patients, and this partnership with RxLightning exemplifies our values in every way. More importantly, however, it supports our patients and eases some of the financial burdens they may experience when requiring specialty medications.”

For more information about how AON is working toward easing administrative burdens for community oncology practices and delivering patient-centered care, visit https://www.aoncology.com/blog/.

To learn more about how RxLightning is revolutionizing the face of specialty pharmacy by making the complex simple, visit https://www.rxlightning.com/.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

About RxLightning
Founded in New Albany, Indiana in 2020, RxLightning digitizes, automates and streamlines the historically complicated manual enrollment process of starting a patient on specialty medications. Specialty medications are expected to account for 70% of new medication launches through 2023. With RxLightning, healthcare providers can quickly and easily complete the enrollment process for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication and accelerate the speed of therapy for patients. Learn more at rxlightning.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

Kriste Goad
RxLightning
Kg@growwithfuoco.com

American Oncology Network Expands Footprint in Georgia with the Addition of Cancer and Blood Specialists of Georgia in Atlanta

/in /by

New oncology-hematology clinic opens in mid-September, delivering additional cancer care and treatments
to the Johns Creek community.

FORT MYERS, Fla. and JOHNS CREEK, Ga., September 20, 2022 – American Oncology Network, LLC (AON) is pleased to announce the opening of Cancer and Blood Specialists of Georgia (CBSG), a new community-based oncology practice located in Johns Creek. The CBSG clinic is located at 6985 McGinnis Ferry Road, Suite 100, is set to open on September 22 and is accepting new patients.

The CBSG team includes Board-certified medical oncologist Sreekanth Reddy, MD, who will provide a comprehensive range of treatments for patients diagnosed with cancer and blood disorders. Dr. Reddy has over 18 years of experience treating oncology and hematology patients in the metro-Atlanta area.

CBSG is a partnering practice with AON, a nationwide network of community-based oncology practices. AON supports hometown practices, their physicians and patients to ensure the latest in cancer care and treatments are readily available and accessible at the local level. Through the partnership, CBSG is able to provide multiple services to patients such as infusion therapy, centralized laboratory and pathology, oral cancer medications and financial counseling.

“Our partnership with AON is a valuable one that allows our healthcare team to be patient-first and focused on delivering high-quality care and services to every patient,” said Dr. Reddy, lead medical oncologist at CBSG. “Through the partnership, our patients benefit greatly and will have access to a plethora of care and services, including care management, that will have a great influence on their overall health journey.”

“Community-based practices are the heart and soul of delivering patient-first care that is accessible and affordable, which is very important in cancer care,” said Brad Prechtl, MBA, AON’s president and chief development officer. “Dr. Reddy is dedicated to ensuring patient-first care remains intact in his practice. I am honored to say that we are gaining a well-practiced physician who is dedicated to driving patient-first cancer care in his community.”

“We are excited to extend a warm AON welcome to Dr. Reddy and the team at Cancer and Blood Specialists of Georgia,” said Todd Schonherz, AON’s chief executive officer. “Dr. Reddy is an excellent physician and brings ample experience to the oncology network in and around Atlanta. We look forward to supporting him, his practice as well as his patients.”

For more information about Cancer and Blood Specialists of Georgia, visit https://www.cancerbloodspecialistsga.com/.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.

About Cancer and Blood Specialists of Georgia
Specialists in the diagnosis and treatment of cancer and blood disorders, Cancer and Blood Specialists of Georgia providers have been serving patients in the Johns Creek, Georgia and surrounding Atlanta areas for more than 18 years. As a community-based practice, we offer a full range of exceptional cancer services, providing the highest quality treatment based on research and focused on the whole person.

Contact for more information:
Caroline Hewitt, Vice President of  Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

American Oncology Network’s Laboratory Receives CAP Accreditation

/in /by

After a rigorous on-site inspection, AON announces its laboratory has been granted full CAP accreditation through 2024.

FORT MYERS, Fla., September 19, 2022 – The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to American Oncology Network, LLC (AON)’s laboratory based on the results of a recent on-site inspection as part of the CAP’s Accreditation Programs. The accreditation was granted on July 25, and the next on-site inspection for accreditation renewal will take place in early 2025.

AON Vice President of Laboratory Services Curtiss McNair, Jr., MBA, MT, was advised of this national recognition and congratulated for the excellence of the services being provided. AON’s clinical laboratory is one of more than 8,000 CAP-accredited facilities worldwide.

“We are honored to receive the CAP accreditation,” said McNair. “We continuously look for opportunities to improve our processes and ensure we are providing laboratory services that align with federal regulations — and patient expectations. This accreditation keeps us accountable to our promises and the requirements of offering quality laboratory services.”

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, which began in the early 1960s, as being equal to or more stringent than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

AON Chief Medical Officer Dr. Stephen “Fred” Divers upon learning of the laboratory’s accreditation said, “We drive patient-centered care always, no matter the purpose of the interaction. Our laboratory works tirelessly to ensure we are always providing better service to our patients, and our receipt of accreditation shows our dedication to delivering better patient care and services. The CAP accreditation is well-known in the industry, and we are proud to be a CAP-accredited laboratory.”

AON’s laboratory accreditation can be verified through the CAP’s Accredited Laboratory and Biorepository Directory.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

Oncology-Hematology Clinic in Meridian Rebrands to Gem State Cancer & Blood Specialists

/in /by

Summit Cancer Centers rebrands part of the practice to Gem State Cancer & Blood Specialists
to better serve local cancer patients.

MERIDIAN, Idaho, September 12, 2022 – Medical Oncologist Dr. Stephanie Hodson announced the rebranding of her practice from Summit Cancer Centers to Gem State Cancer & Blood Specialists. The clinic changed its name on September 12 and is accepting new patients.

Gem State Cancer & Blood Specialists is one of 25 practices that are part of the American Oncology Network, LLC (AON), a growing national network of community-based oncology practices, that has access to resources and support to ensure patients continue to receive high-quality cancer care within their own community. The clinic is located at 2855 E. Magic View Drive, Suite B, and delivers personalized oncology and hematology care.

The practice is equipped to deliver the latest care and treatments for patients diagnosed with cancer and blood disorders and has been specifically designed to deliver patient care in an environment that promotes health and wellness. Services provided at the clinic are vast and include an in-house lab and pathology, a specialty pharmacy, chemotherapy, care management and financial counseling. The clinic also offers Paxman scalp cooling for hair-loss prevention during chemotherapy treatment.

“The Gem State Cancer & Blood Specialists brand captures the beauty that is Idaho and is an ode to the state’s gem heritage,” said Dr. Hodson. “Being born and raised in Idaho, it is an honor to serve my community in such a way that brings about improved health outcomes for those fighting cancer and blood disorder diagnoses.”

Boise native Dr. Stephanie Hodson is a Board-certified medical oncologist and hematologist. She brings over 20 years’ experience treating various malignancies and hematologic disorders. She obtained her medical degree from the University of Washington and completed her fellowship training in medical oncology and hematology at Oregon Health Sciences University. Joining her at Gem State Cancer & Blood Specialists is certified physician assistant Katherine Mondada.

“The growth and expansion of Dr. Hodson’s practice to Gem State Cancer & Blood Specialists show the level of commitment to delivering cancer care options to the residents of Meridian, Boise and surrounding communities,” said AON Chief Executive Officer Todd Schonherz. “We look forward to continuing to support Dr. Hodson in her initiatives to deliver top-notch care and services to her patients.”

To learn more about Gem State Cancer & Blood Specialists, visit www.GemStateCancerBloodSpecialists.com.

###

About Gem State Cancer & Blood Specialists
Specialists in the diagnosis and treatment of cancer and blood disorders, Gem State Cancer & Blood Specialists providers have been serving patients in the Meridian and Boise, Idaho, areas for more than 20 years. As a community-based practice, we offer a full range of exceptional cancer services, providing the highest quality treatment based on research and focused on the whole person.

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.

Contact for more information:
Caroline Hewitt, Vice President of  Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

Impressive Results with Oncology Care Model Confirm American Oncology Network at the Forefront of Patient-Centered Cancer Care

/in /by

Practices using the value-based care approach improved patient care while saving costs.

FORT MYERS, Fla., August 22, 2022 – The American Oncology Network, LLC (AON), a fast-growing network of community-based oncology practices, is excited to report its successes as an active participant in the Oncology Care Model (OCM). These results come a few weeks after the OCM’s discontinuation on June 30, 2022.

Nineteen AON community oncology clinics were part of the initial 200 practices across the nation that were approved to participate in the OCM after successfully meeting the criteria required by the Centers for Medicare and Medicaid Services (CMS) in 2018. These clinics were Medicare-enrolled providers whose practices 1) offered advanced patient services such as patient navigation functions, comprehensive care plans containing the 13 components of the Institute of Medicine Care Management Plan, around-the-clock access to a care manager or appropriate member of the care team, and nationally-recognized therapy treatments; 2) utilized data to improve care services and care quality; and 3) used electronic health records.

AON delivered the OCM through their in-house Care Management Program that is founded on the value-based care model and an integrated system of seamless communication, coordination and patient care for better health outcomes. Upon closure of the OCM, AON achieved significant improvements in overall patient care and cost expenditure for its practices operating under the OCM’s “two-sided risk” model.

AON’s OCM practices reported a 2.6% decrease in expenditures compared to other OCM practices and a 4.9% decrease in expenditures compared to all practices providing cancer care.

Participation in the OCM increased patient satisfaction, reduced emergency room visits leading to hospital admission by 14.69% and inpatient admissions by 7.8%, enhanced care equity, and improved efficiency in care coordination.

Additionally, AON reported a reduction in waste and unnecessary expenses as a result of its implementation of the tools and technologies designed to support effective decision-making. These consisted of an internal formulary navigator that assisted with value-based clinical pathway and regimen selection, the use of data analytics to determine process and cost savings opportunities, and the reliance on electronic medical records (EMR).

“We are excited to see these particular improvements in the areas of healthcare service and delivery,” said AON Chief Executive Officer Todd Schonherz. “It shows how the industry as a whole is making great strides to bring accessible and affordable care to all and is working toward the value-based care model that we, at AON, believe in.”

Other key achievements reported by AON practices included OCM quality scores exceeding 90% as well as:

  • A 6.1% decrease in the costs of total care.
  • A 28% decrease in AON facilities’ inpatient expenses.
  • An increase in the use of biosimilar drugs and a decrease in patient prescription expenses.

“We have witnessed positive outcomes and experiences — for both our practices and patients — who operate under the OCM. The program allowed our physicians to deliver better care and services at decreased costs to our Medicare beneficiaries,” said Dr. Stephen “Fred” Divers, AON chief medical officer and medical oncologist at Genesis Cancer and Blood Institute. “Oncology care can be a financial burden for many, and the OCM provided an episode-based payment system that helped cap healthcare costs while maintaining the quality of care being delivered.”

The OCM is a program developed by the Centers for Medicare & Medicaid Innovation (CMS Innovation Center) with the goal to decrease healthcare costs for Medicare-specific patients undergoing either chemotherapy or hormonal therapy as treatment. The program emphasized care quality over care quantity, encouraging physicians to adopt the patient-first mentality. An average cost savings of $297 less per six-month episode was recorded for all participating Medicare patients and providers.

“Being a part of the OCM has motivated us to continue delivering the same quality of care and follow the same processes despite the program’s end,” said Roberta Kafora, senior director of nursing, care management and value-based care at AON. “We are excited about the next step in our value-based care initiative, the Principal Care Management Program, that we officially launched on July 1, 2022.” 

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 86 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

American Oncology Network Ranks No. 107 on the 2022 Inc. 5000 Annual List

/in /by

AON receives ranking no. 107 among America’s fastest-growing private companies
and no. eight among health services.

FORT MYERS, Fla., August 18, 2022 – Earlier this week, Inc. 5000 announced that the American Oncology Network, a fast-growing network of community oncology practices, is ranked number 107 on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. AON also received the number eight position in the health services category.

The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment — its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“We are honored to be recognized as one of the nation’s fastest-growing private companies by Inc.,” said AON Chief Executive Officer Todd Schonherz. “At AON, we believe the key to accessible and equitable healthcare lies in the strength of community healthcare practices, which is why we strive to support community oncology practices, large and small. This recognition is a reminder that we are taking the right steps in forwarding our mission by providing support and resources for hometown oncology practices and breaking down barriers to cancer care.”

The companies on the 2022 Inc. 5000 list are not only successful, but also demonstrate resilience amid supply chain woes, labor shortages and the ongoing impact of COVID-19. Among the top 500, the average median three-year revenue growth rate soared to 2,144 percent. Together, those companies added more than 68,394 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000. The top 500 companies are featured in the September issue of Inc. magazine, which will be available on August 23.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work and rising to the challenges of today.”

“We are excited to celebrate receiving this esteemed award with our physicians, practices, team members and patients,” said Schonherz. “I’d like to extend an additional congratulations to all companies that are on this year’s Inc. 5000 list.”

For more information about AON, visit https://www.aoncology.com/.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 86 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

More about Inc. and the Inc. 5000
Methodology
Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at https://www.inc.com/inc5000.

About Inc.
The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

For more information on the Inc. 5000 Conference & Gala, visit https://conference.inc.com/.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

American Oncology Network Comments Against CMS’ 2023
Outpatient Prospective Payment System

/in /by

The new proposal will have grave effects on the sustainability of community oncology practices.

FORT MYERS, Fla., August 15, 2022 – The Centers for Medicare & Medicaid Services (CMS) announced its proposed CY 2023 Outpatient Prospective Payment System (OPPS), which has sparked concern for the community-oncology advocate American Oncology Network (AON).

Despite the Biden-Harris Administration’s goal of increasing health equity across all geographies, promoting healthy competition throughout the healthcare industry and driving toward value-based and patient-centered care, CMS’ proposal for 2023 will undoubtedly cripple community healthcare practices.

Most concerning for community-based practices are the increase in the 340B drug pricing to the average sale price plus 6% and the rise in Medicare reimbursement rates of 2.7%. While practices affiliated with healthcare systems and hospitals reap the benefits of the OPPS proposals, independent community practices will have to reduce their payment rates to maintain neutrality and receive a decrease in Medicare payments — limiting their ability to continue providing quality care, services and medications to their patients.

“For more rural practices, like many of the community oncology practices we support, these are alarming recommendations,” said AON Chief Executive Offer Todd Schonherz. “If these actions come to fruition in 2023, they have the potential to threaten the success and growth of small-town clinics, which will then suffer financially and struggle to effectively compete with larger practices and healthcare systems that qualify under 340B.”

“Community-based clinics provide high-quality care, services and resources that are affordable and accessible,” said AON Chief Medical Officer and Genesis Cancer and Blood Institute medical oncologist Stephen “Fred” Divers, MD. “These practices are critical players in closing the cancer care gap and driving healthcare equity. If they do not receive the support needed to continue providing care in their communities, our healthcare system has done a disservice to them and failed.”

CMS is accepting comments on the proposed OPPS through September 13, 2022 and the final ruling is scheduled for November 2022.

“We encourage practices, providers and networks to comment against the proposed OPPS to safeguard community-based care and keep healthcare affordable and accessible,” said Divers.

For more information about CMS’ 2023 OPPS, visit https://www.cms.gov/newsroom/fact-sheets/cy-2023-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 86 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

American Oncology Network and Cancer & Blood Specialists of Arizona Welcome Samrat Sanghvi, MD

/in /by

Casa Grande, Ariz., August 3, 2022 – The American Oncology Network, LLC (AON) and Drs. Carlos Arce-Lara and Ramon Mourelo of Cancer & Blood Specialists of Arizona (CBSA), are pleased to announce that radiation oncologist Samrat Sanghvi, MD, has joined the AON community oncology practice in Casa Grande.

Dr. Sanghvi earned his Doctor of Medicine at Georgetown University School of Medicine in Washington, DC, where he received the Warwick Evans Radiation Oncology Award. He then completed an internship in internal medicine at the Virginia Commonwealth University in Richmond and a residency in radiation oncology at Loma Linda University in California.

While at Loma Linda, he served as Chief Resident of the Radiation Oncology program. He also had the opportunity to experience international radiation oncology in Germany and more recently, volunteering in a radiation oncology clinic in Nepal.

“We are excited to have Dr. Sanghvi join our practice. He treats a wide range of cancers as well as benign conditions and has extensive experience with Stereotactic Body Radiation Therapy treatments,” said CBSA medical oncologist Dr. Carlos Arce-Lara.

CBSA has numerous locations across the state and continues to grow. The practice currently consists of nineteen providers including seven medical oncologists, two gynecologic oncologists, a radiation oncologist, a general surgeon and eight nurse practitioners.

“Radiation therapy is an important weapon in the battle against cancer. Having Dr. Sanghvi join the team with his expertise will benefit not only the Casa Grande community but the entire network of community oncology practices,” said AON President and Chief Development Officer Brad Prechtl, MBA.

“We are very pleased to welcome Dr. Sanghvi,” added AON Chief Executive Officer Todd Schonherz. “The Casa Grande practice brings together multispecialty services including medical, surgical, radiation oncology, nutrition and others. It is the only facility in all of Pinal County providing true comprehensive, multidisciplinary cancer care. The collaborative environment is designed to make cancer care more accessible and easier for patients, enabling them to stay in Case Grande for treatment, instead of traveling to institutions in other cities.”

Dr. Sanghvi will begin on August 3 and is accepting new patients.

###

About Cancer & Blood Specialists of Arizona: (CancerBloodSpecialistsAZ.com)
Cancer & Blood Specialists of Arizona is a community-based Medical Oncology and Hematology, Gynecologic Oncology, Radiation Oncology and General Surgery practice providing treatment for patients diagnosed with all types of cancer and blood disorders. We are experienced physicians, nurse practitioners, nurses and clinical support staff providing compassionate, patient-centered care in Phoenix, Flagstaff and Casa Grande, Arizona, and surrounding areas. Our physicians have deep roots in the communities we serve delivering the highest quality cancer treatment that is based on cutting-edge research.

About American Oncology Network, LLC: (AONcology.com)
American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most – providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences will be at the very pinnacle of cancer care today.

For More Information, Contact:
American Oncology Network, LLC
Caroline Hewitt, Vice President of  Marketing
Caroline.Hewitt@AONcology.com

New Location, Same Dedicated Care:
Waverly Hematology Oncology Announces Relocation of Clinic

/in /by

Community oncology clinic relocates to continue providing enhanced cancer care to Wake County.

CARY, N.C., (August 2, 2022) – Community oncology practice Waverly Hematology Oncology (Waverly) announces the relocation of its clinic to 210 Ashville Avenue, Suite 440, in Cary effective August 1, 2022. The clinic will begin seeing patients, new and existing, starting August 2, 2022, at the new location.

“Our relocation comes from our steadfast growth and commitment to providing our patients with an environment that allows us to be patient-centered in our care approach,” said Dr. Mark Graham, leading medical oncologist and hematologist at Waverly. “We have been a part of Wake County for 18 years and are honored to continue serving our town and patients at our new clinic.”

Waverly’s new location, which is only a two-minute drive from the practice’s current location, is situated in the Medical Park of Cary, which houses other healthcare practices including complimentary care and services for oncology patients. The space has been designed specifically for delivering personalized cancer care to oncology and hematology patients.

“Great dedication has been taken during the setup process to ensure the space is well equipped to treat multiple cancer diagnoses and is an environment that inspires healing and wellness,” said Graham. “Cancer treatment can be an uncomfortable experience and physically and mentally taxing for patients, their families and their caregivers. We want to ensure that everyone who walks into our clinic feels a sense of peace and at home, which is the beauty and mission of community oncology.”

Waverly is a partner of the American Oncology Network (AON), which is an expanding network of community oncology practices across the United States. Since 2004, the clinic has offered medical oncology, chemotherapy, infusion therapy, laboratory services and an on-site pharmacy.

The practice also houses the oldest cancer genetics clinic in the county and is home to the area’s first formal cancer Survivor Clinic that serves over 2,000 breast cancer survivors and those at high risk for developing the disease. These services will continue to be available at the new location.

“We extend our appreciation to and applaud Waverly Hematology Oncology for their unwavering commitment to their community,” said AON Chief Executive Officer Todd Schonherz. “The relocation of their practice to a space that helps them deliver top-notch cancer care and treatment exemplifies their dedication to their patients as well as their mission to enhancing oncology in Cary and the surrounding communities.”

For more information about Waverly, visit www.waverlyhematologyoncology.com. For more information about AON, visit www.aoncology.com.

###

About Waverly Hematology Oncology
Waverly Hematology Oncology (Waverly) offers centralized easy access to cancer care for Cary, North Carolina patients and is conveniently located at the intersection of two major highways, Route 1 and Highway 64 (Tryon Road). In private practice since 2004, Waverly represents one medical oncologist four physician assistants and a team of over 40 employees, 17 of which have over 10 years of employment. A community-based practice, Waverly offers medical oncology, chemotherapy, infusion therapy, laboratory services, an on-site pharmacy and has the oldest cancer genetics clinic in Wake County. For over 30 years Dr. Graham has been an active clinical investigator through the NCI Community Oncology Research Program (NCORP), a cancer clinical trials network in the U.S., leading in patient accrual and data. Waverly is also the only Triangle site of the Southeast Clinical Oncology Research (SCOR), representing over 20 communities in six states. Waverly expanded the practice in 2015 and opened the first formal Cancer Survivorship Clinic in the county that now includes over 2,000 breast cancer survivors and those at high risk for breast cancer.

For over 30 years Dr. Graham has been an active clinical investigator through the NCI Community Oncology Research Program (NCORP), a cancer clinical trials network in the U.S., leading in patient accrual and data. Waverly is also the only Triangle site of the Southeast Clinical Oncology Research (SCOR), representing over 20 communities in six states.

Waverly expanded the practice in 2015 and opened the first formal Cancer Survivorship Clinic in the county that now includes over 2,000 breast cancer survivors and those at high risk for breast cancer.

About American Oncology Network, LLC
The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients. The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care. AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com